These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 3484964)

  • 21. An inhibitor of plasminogen activation from human placenta. Purification and characterization.
    Wun TC; Reich E
    J Biol Chem; 1987 Mar; 262(8):3646-53. PubMed ID: 3102492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease.
    Leiper K; Croll A; Booth NA; Moore NR; Sinclair T; Bennett B
    J Clin Pathol; 1994 Mar; 47(3):214-7. PubMed ID: 8163691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2.
    Thorsen S; Philips M; Selmer J; Lecander I; Astedt B
    Eur J Biochem; 1988 Jul; 175(1):33-9. PubMed ID: 3136015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta.
    Hu ZY; Liu YX; Liu K; Byrne S; Ny T; Feng Q; Ockleford CD
    J Anat; 1999 Feb; 194 ( Pt 2)(Pt 2):183-95. PubMed ID: 10337950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer.
    Grøndahl-Hansen J; Agerlin N; Munkholm-Larsen P; Bach F; Nielsen LS; Dombernowsky P; Danø K
    J Lab Clin Med; 1988 Jan; 111(1):42-51. PubMed ID: 3121772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fibrinolytic components in fetal membranes and amniotic fluid.
    Watanabe T; Araki M; Mimuro J; Tamada T; Sakata Y
    Am J Obstet Gynecol; 1993 Apr; 168(4):1283-9. PubMed ID: 7682753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration.
    Lucore CL; Fujii S; Sobel BE
    Circulation; 1989 Jun; 79(6):1204-13. PubMed ID: 2498004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunological relationship between plasminogen activator inhibitors from different sources.
    Urdén G; Chmielewska J; Carlsson T; Wiman B
    Thromb Haemost; 1987 Feb; 57(1):29-34. PubMed ID: 2438797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Release pattern of the vascular plasminogen activator and its inhibitor in human postvenous occlusion plasma as assessed by a spectrophotometric solid-phase fibrin-tPA activity assay.
    Anglés-Cano E; Boutière B; Arnoux D; Masson C; Contant G; Benchimol P; Sampol J
    Thromb Haemost; 1987 Oct; 58(3):843-9. PubMed ID: 3124285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An enzyme-linked immunosorbent assay for urokinase-type plasminogen activator (u-PA) and mutants and chimeras containing the serine protease domain of u-PA.
    Declerck PJ; Van Keer L; Verstreken M; Collen D
    Thromb Haemost; 1992 Jan; 67(1):95-100. PubMed ID: 1377417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibrinolysis during normal human pregnancy: complex inter-relationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time.
    Wright JG; Cooper P; Astedt B; Lecander I; Wilde JT; Preston FE; Greaves M
    Br J Haematol; 1988 Jun; 69(2):253-8. PubMed ID: 3134043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies.
    Nielsen LS; Grøndahl-Hansen J; Andreasen PA; Skriver L; Zeuthen J; Danø K
    J Immunoassay; 1986; 7(3):209-28. PubMed ID: 3091639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioimmunoassay (BIA) of tissue plasminogen activator (t-PA) and its specific inhibitor (t-PA/INH).
    Mahmoud M; Gaffney PJ
    Thromb Haemost; 1985 Jun; 53(3):356-9. PubMed ID: 3931284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Levels of tissue-type plasminogen activator and plasminogen activator inhibitor 1 in disseminated intravascular coagulation syndrome].
    Fukao H; Yamamoto K; Matsuo O
    Rinsho Byori; 1991 Jul; 39(7):720-6. PubMed ID: 1920864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A plasminogen activator inhibitor (PAI-2) circulates in two molecular forms during pregnancy.
    Booth NA; Reith A; Bennett B
    Thromb Haemost; 1988 Feb; 59(1):77-9. PubMed ID: 3129811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
    Siegbahn A; Ruusuvaara L
    Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased concentration of the fast-acting plasminogen activator inhibitor in plasma associated with familial venous thrombosis.
    Jørgensen M; Bonnevie-Nielsen V
    Br J Haematol; 1987 Feb; 65(2):175-80. PubMed ID: 3103670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies.
    Darras V; Thienpont M; Stump DC; Collen D
    Thromb Haemost; 1986 Dec; 56(3):411-4. PubMed ID: 3105111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Interaction of plasminogen activator of urokinase type with human serum].
    Vakulina OP; Popkova EV; Isachenkov VA
    Vopr Med Khim; 1988; 34(4):32-6. PubMed ID: 3143185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.
    Pöllänen J; Vaheri A; Tapiovaara H; Riley E; Bertram K; Woodrow G; Stephens RW
    Proc Natl Acad Sci U S A; 1990 Mar; 87(6):2230-4. PubMed ID: 2138329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.